Opinion|Videos|April 4, 2025
Comparing Standard-of-Care Antibiotics for Uncomplicated UTIs
Panelists discuss how standard-of-care antibiotics for uncomplicated urinary tract infections (UTIs) show varying efficacy, with nitrofurantoin and fosfomycin demonstrating superior response rates (85%-95%) compared with trimethoprim/sulfamethoxazole (70%-80% due to increasing resistance) and first-generation cephalosporins (80%-90%), and how cost-effectiveness depends on local resistance patterns, patient adherence to dosing schedules, medication costs and insurance coverage, treatment duration, recurrence rates, comorbidities, and potential adverse effects requiring additional interventions.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do current standard-of-care antibiotics such as nitrofurantoin, trimethoprim/sulfamethoxazole, fosfomycin, and first-generation cephalosporins compare in terms of patient response rates for uncomplicated UTIs?
- What factors may contribute to one drug being more cost-effective than another in specific patient populations?
Advertisement
Related to this article
Naim Alkhouri, MD, on when to judge MASH treatment response, counseling on weight and muscle loss, primary care screening, and future trial end points.
Pharmacists outline new oncologic therapeutics, from pancreatic cancer to myeloma, and what high prices and crowded markets mean for payers.
Invivyd presented preclinical IDWeek 2026 data on VMS063, an investigational antibody that neutralized B3 and D8 measles variants in vitro.
Sphingolipid profiles in plasma and breath condensate differed between IPF and f-HP and tracked with disease severity, CHEST 2026 data show.
The FDA granted accelerated approval to the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP).
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.
Advertisement
Advertisement
Trending on AJMC
1
NYC Marathon Death Puts Rhabdomyolysis Risk Factors in Focus
2
Real-World Evidence, Rare Liver Disease Data Headline Kidney Week 2026
3
Disease Extent Linked to Complications After Deep Endometriosis Surgery
4
Cranberry Supplement Tied to Greater OAB Score Reductions in Pilot Trial
5